Relapse in FEV1 decline after steroid withdrawal in COPD

Chest

Volumn 148, Issue 2, 2015, Pages 389-396

  Kunz, Lisette I Z ^a   Postma, Dirkje S ^b   Klooster, Karin ^b   Lapperre, Thérese S ^a,c   Vonk, Judith M ^b   Sont, Jacob K ^a   Kerstjens, Huib A M ^b   Snoeck Stroband, Jiska B ^a   Hiemstra, Pieter S ^a   Sterk, Peter J ^d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; PLACEBO; STEROID; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; DRUG COMBINATION; FLUTICASONE; FLUTICASONE, SALMETEROL DRUG COMBINATION; GLUCOCORTICOID; SALBUTAMOL;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DRY POWDER INHALER; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RESPIRATORY TRACT ALLERGY; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; COHORT ANALYSIS; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENT DISEASE; TREATMENT WITHDRAWAL;

ADMINISTRATION, INHALATION; AGED; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; COHORT STUDIES; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RECURRENCE; WITHHOLDING TREATMENT;

EID: 84939231286     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-3091     Document Type: Article

References (25)

1. Vestbo J, Hurd SS, Agust AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013; 187 (4): 347-365.
2. Gershon AS, Campitelli MA, Croxford R, et al. Combination long-acting b-agonists and inhaled corticosteroids compared with long-acting b-agonists alone in older adults with chronic obstructive pulmonary disease. J AMA. 2014; 312 (11): 1114-1121.
3. Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012; 7: CD002991.
4. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008; 178 (4): 332-338.
5. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000; 320 (7245): 1297-1303.
6. Soriano JB, Sin DD, Zhang X, et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. C hest. 2007; 131 (3): 682-689.
7. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al; Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2009; 151 (8): 517-527.
8. Magnussen H, Disse B, Rodriguez-Roisin R, et al; WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014; 371 (14): 1285-1294.
9. Wouters EFM, Postma DS, Fokkens B, et al; COSMIC (COPD and Seretide: a Multi-Center Intervention and Charac terization) Study Group. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax. 2005; 60 (6): 480-487.
10. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med. 2002; 166 (10): 1358-1363.
11. Croxton TL, Weinmann GG, Senior RM, Hoidal JR. Future research directions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002; 165 (6): 838-844.
12. Rabe KF, Hurd S, Anzueto A, et al; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007; 176 (6): 532-555.
13. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992; 145 (6): 1321-1327.
14. van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes. 2003; 1 (1): 13.
15. Calverley PMA, Spencer S, Willits L, Burge PS, Jones PW; ISOLDE Study Group. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest. 2003; 124 (4): 1350-1356.
16. Kocks JW, Tuinenga MG, Uil SM, van den Berg JW, Sthl E, van der Molen T. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res. 2006; 7: 62.
17. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD. 2005; 2 (1): 75-79.
18. Prosperini G, Rajakulasingam K, Cacciola RR, et al. Changes in sputum counts and airway hyperresponsiveness aft er budesonide: monitoring anti-inflammatory response on the basis of surrogate markers of airway inflammation. J Allergy Clin Immunol. 2002; 110 (6): 855-861.
19. Takaku Y, Nakagome K, Kobayashi T, et al. Changes in airway inflammation and hyperresponsiveness aft er inhaled corticosteroid cessation in allergic asthma. Int Arch Allergy Immunol. 2010; 152 (suppl 1): 41-46.
20. Grönke L, Kanniess F, Holz O, Jörres RA, Magnussen H. The relationship between airway hyper-responsiveness, markers of inflammation and lung function depends on the duration of the asthmatic disease. Clin Exp Allergy. 2002; 32 (1): 57-63.
21. van den Berge M, Vonk JM, Gosman M, et al. Clinical and inflammatory determinants of bronchial hyperresponsiveness in COPD. Eur Respir J. 2012; 40 (5): 1098-1105.
22. Ingebrigtsen TS, Marott J, Nordestgaard BG, et al. Low use and adherence to maintenance medication in chronic obstructive pulmonary disease in the general population. J Gen Intern Med. 2015; 30 (1): 51-59.
23. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013; 68 (11): 1029-1036.
24. Wedzicha JA. Oral corticosteroids for exacerbations of chronic obstructive pulmonary disease. Thorax. 2000; 55 (suppl 1): S23-S27.
25. Van Overveld FJ, Demkow U, Górecka D, De Backer WA, Zieliński J. Differences in responses upon corticosteroid therapy between smoking and non-smoking patients with COPD. J Physiol Pharmacol. 2006; 57 (suppl 4): 273-282.